Is B-cell depletion still a good strategy for treating immune thrombocytopenia?

Presse Medicale

Volumn 43, Issue 4P2, 2014, Pages

  Godeau, Bertrand ^a   Stasi, Roberto ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; BORTEZOMIB; CD20 ANTIBODY; CD22 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; PLACEBO; RITUXIMAB; VELTUZUMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIGEN EXPRESSION; AUTOIMMUNE CYTOPENIA; B LYMPHOCYTE; CAUSE OF DEATH; CELL COMPARTMENTALIZATION; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOPENIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFUSION RELATED REACTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84898854935     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.01.011     Document Type: Short Survey

References (45)

1. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011, 9:262-273.
2. Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: pathogenic and clinical diversity. Blood 2009, 113:6511-6521.
3. McKenzie C.G., Guo L., Freedman J., Semple J.W. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013, 163:10-23.
4. Sprague C.C., Harrington W.J., Lange R.D., Shapleigh J.B. Platelet transfusions and the pathogenesis of idiopathic thrombocytopenic purpura. J Am Med Assoc 1952, 150:1193-1198.
5. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
6. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
7. Cooper N., Stasi R., Cunningham-Rundles S., Cesarman E., McFarland J.G., Bussel J.B. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol 2012, 158:539-547.
8. Stasi R., Del Poeta G., Stipa E., Evangelista M.L., Trawinska M.M., Cooper N., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
9. Stasi R., Cooper N., Del Poeta G., Stipa E., Laura Evangelista M., Abruzzese E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
10. Audia S., Samson M., Mahévas M., Ferrand C., Trad M., Ciudad M., et al. Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood 2013, 122:2477-2486.
11. Audia S., Samson M., Guy J., Janikashvili N., Fraszczak J., Trad M., et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011, 118:4394-4400.
12. Mahévas M., Patin P., Huetz F., Descatoire M., Cagnard N., Bole-Feysot C., et al. B-cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells with unique characteristics. J Clin Invest 2013, 123:432-442.
13. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
14. Chugh S, Arnold DM, Lim W, Crowther MA, Darvish-Kazem S. Systematic review and meta-analysis of rituximab for the treatment of immune thrombocytopenia in adults. New Orleans, USA: 55th ASH annual meeting; 2013. abstr 1681 [Publication électronique]. https://ash.confex.com/ash/2013/webprogram/Paper59617.html.
15. Godeau B., Porcher R., Fain O., Lefrère F., Fénaux P., Cheze S., et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura. Results of a multi-center prospective phase 2 study. Blood 2008, 112:999-1004.
16. Auger S., Duny Y., Rossi J.F., Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012, 158:386-398.
17. Ghanima W, Khelif A, Benromdhan N, Waage A, Tjonnfjord GE, Michel M, et al. Rituximab as second line treatment for adult immune thrombocytopenia (itp): a multicentre, randomized, double blind, placebo-controlled study-the Ritp Study. New Orleans, USA: 55th ASH annual meeting; 2013. abstr 449 [Publication électronique]. https://ash.confex.com/ash/2013/webprogram/Paper64367.html.
18. Patel V.L., Mahévas M., Lee S.Y., Stasi R., Cunningham-Rundles S., Godeau B., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
19. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalop- athy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2008, 113:4834-4840.
20. Venna N., Gonzalez R.G., Camelo-Piragua S.I. Case 11-2010-a 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging. N Engl J Med 2010, 362:1431-1437.
21. Gottenberg J.E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. AutoImmunity and Rituximab registry and French Society of Rheumatology Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
22. Khellaf M, Fain O, Terriou L Viallard JF, Cheze S, Roudot-Thoraval F, et al. Safety and efficacy of rituximab in adult's immune thrombocytopenia (ITP): results after one-year of follow-up in 252 patients from the prospective French ITP-Ritux Registry. New Orleans, USA: 55th ASH annual meeting; 2013. abstr 450. [Publication électronique]. https://ash.confex.com/ash/2013/webprogram/Paper58866.html.
23. Cooper N., Arnold D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010, 149:3-13.
24. Levy R., Mahevas M., Galicier L., Boutboul D., Fain O., Khellaf M., et al. Survenue d'une hypogammaglobulinémie symptomatique à distance d'un traitement par rituximab dans le cadre d'un purpura thrombopénique immunologique: une complication potentiellement grave qui doit être recherchée. À propos de trois observations. Rev Med Interne 2013, 34(S1):A48-A49.
25. Nazi I., Kelton J.G., Larché M., Snider D.P., Heddle N.M., Crowther M.A., et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013, 122:1946-1953.
26. Provan D., Butler T., Evangelista M.L., Amadori S., Newland A.C., Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007, 92:1695-1698.
27. Zaja F., Battista M.L., Pirrotta M.T., Palmieri S., Montagna M., Vianelli N., et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2008, 93:930-933.
28. Zaja F., Vianelli N., Volpetti S., Battista M.L., Defina M., Palmieri S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010, 85:329-334.
29. Mahévas M., Ebbo M., Audia S., Bonnotte B., Schleinitz N., Durand J.M., et al. Efficacy and safety of rituximab given at 1000mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol 2013, 88:858-861.
30. Hasan A., Michel M., Patel V., Stasi R., Cunningham-Rundles S., Leonard J.P., et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009, 84:661-665.
31. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
32. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
33. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
34. Zaja F., Baccarani M., Mazza P., Bocchia M., Gugliotta L., Zaccaria A., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
35. Gudbrandsdottir S., Birgens H.S., Frederiksen H., Jensen B.A., Jensen M.K., Kjeldsen L., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013, 121:1976-1981.
36. Lee CS, Imahiyerobo A, Thompson M, Karaev MI, Ghanima W, Bussel JB. Rituximab combined with three cycles of high dose dexamethasone provides a long-term response rate similar to that of splenectomy in patients with immune thrombocytopenia (ITP) of duration less than 2 years. New Orleans, USA: 55th ASH annual meeting; 2013. abstr 2310. [Publication électronique]. https://ash.confex.com/ash/2013/webprogram/Paper62543.html.
37. Xu M, Qin P, Dong X, Li J, Zhang H, Wang X, et al. Recombinant human thrombopoietin and rituximab vs rituximab monotherapy in corticosteroid-resistant primary immune thrombocytopenia: a multicenter randomized study. New Orleans, USA: 55th ASH annual meeting; 2013. abstr 329. [Publication électronique]. https://ash.confex.com/ash/2013/webprogram/Paper62915.html.
38. van Meerten T., Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010, 47:199-210.
39. Liebman H.A., Saleh M.N., Bussel J.B., Negrea O.G., Horne H., Wegener W.A., et al. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol 2013, 162:693-701.
40. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004, 103:1229-1236.
41. Sidiropoulos P.I., Boumpas D.T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13:391-397.
42. Peng J., Liu C., Liu D., Ren C., Li W., Wang Z., et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003, 101:2721-2726.
43. Zhang X.L., Peng J., Sun J.Z., Guo C.S., Yu Y., Wang Z.G., et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2008, 6:158-165.
44. Wallace D.J., Gordon C., Strand V., Hobbs K., Petri M., Kalunian K., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013, 52:1313-1322.
45. Manzi S., Sánchez-Guerrero J., Merrill J.T., Furie R., Gladman D., Navarra S.V., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012, 71:1833-1838.